Ani Pharmaceuticals (ANIP) Other Non-Current Assets (2010 - 2026)

Ani Pharmaceuticals has reported Other Non-Current Assets for 15 years, with the latest figure at $11.6 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 12.24% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 12.24% YoY) and the FY2025 annual result came in at $13.7 million, up 12.16% from the prior year.
• Other Non-Current Assets fell to $11.6 million in Q1 2026 per ANIP's latest filing, from $13.7 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $16.1 million in Q3 2023 and troughed at $2.4 million in Q1 2022.
• A 5-year average of $11.2 million and a median of $12.1 million in 2023 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets plunged 51.32% in 2022, then jumped 279.13% in 2023.
• Over 5 years, Other Non-Current Assets stood at $11.4 million in 2022, then grew by 6.26% to $12.1 million in 2023, then increased by 1.23% to $12.2 million in 2024, then grew by 12.16% to $13.7 million in 2025, then decreased by 15.55% to $11.6 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $11.6 million, $13.7 million, and $12.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.